Compare GROV & IOBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GROV | IOBT |
|---|---|---|
| Founded | 2016 | 2014 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 55.0M | 57.2M |
| IPO Year | N/A | 2021 |
| Metric | GROV | IOBT |
|---|---|---|
| Price | $1.25 | $0.70 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 4 |
| Target Price | $1.60 | ★ $3.50 |
| AVG Volume (30 Days) | 68.4K | ★ 843.3K |
| Earning Date | 11-13-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $180,808,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $16.02 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.02 | $0.32 |
| 52 Week High | $1.95 | $2.79 |
| Indicator | GROV | IOBT |
|---|---|---|
| Relative Strength Index (RSI) | 40.43 | 44.27 |
| Support Level | $1.22 | $0.59 |
| Resistance Level | $1.35 | $0.88 |
| Average True Range (ATR) | 0.05 | 0.08 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 24.32 | 38.36 |
Grove Collaborative Holdings Inc is engaged in providing consumer products. It offers Cleaning accessories, Home and Pantry, Personal care products, Pets supplements and Other products. It is a sustainability oriented consumer products generator. It use connection with consumers to create and curate authentic, disruptive brands and products. Company builds natural products that perform as well as, many consumer packaged goods (CPG) brands (both conventional and natural), while being healthier for consumers and the planet.
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.